Immunotherapy with anti-PD-1 and anti-PD-L1 antibodies has been a highly successful intervention for several types of cancer, including melanoma, renal, cervical, gastric, breast and lung cancer, and it involves preventing the interaction between PD-1 and PD-L1 using antibody binding, blocking T cell suppression in solid tumors. Here, CD274 is linked to melanoma.